课题基金 / 基金详情

CRL 5861 (PURIFIED POLOXAMER 188) IN SICKLE CELL DISEASE & VASO OCCLUSIVE CRISIS

CRL 5861 (PURIFIED POLOXAMER 188) IN SICKLE CELL DISEASE & VASO OCCLUSIVE CRISIS
CRL 5861（纯化的泊洛沙姆 188）治疗镰状细胞病
批准号：
6302992
负责人：
BRIAN K ADLER
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6302992
关键词：
blood disorder chemotherapy blood vessel occlusion clinical research ethylene oxide human subject human therapy evaluation pathologic process sickle cell anemia

项目摘要

项目成果

BRIAN K ADLER的其他基金

相关文献

中文摘要
翻译
由于完成了全国范围内的患者招募，本研究已关闭。 结果表明，该药物具有缩短镰状细胞危象持续时间的强烈趋势，但未达到统计学显著性。药物毒性轻微。 该研究是一项使用Flocer治疗镰状细胞危象的随机、双盲、安慰剂对照试验。
英文摘要
This study has closed due to completion of patient accrual nationwide. The results demonstrated a strong trend, without reaching statistical significance, for the drug reducing the duration of a sickle cell crisis. Toxicity from the drug was mild. The study was a randomized, double blind, placebo controlled trial of the use of Flocer for the treatment of sickle cell crisis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CRL 5861 (PURIFIED POLOXAMER 188) IN SICKLE CELL DISEASE & VASO OCCLUSIVE CRISIS
CRL 5861 (PURIFIED POLOXAMER 188) IN SICKLE CELL DISEASE & VASO OCCLUSIVE CRISIS
CRL 5861 (PURIFIED POLOXAMER 188) IN SICKLE CELL DISEASE & VASO OCCLUSIVE CRISIS
CPC111 IN SICLKE CELL CRISIS--STAGES 1, 2, & 3